Clinical trials: Gastrointestinal Stromal Tumor, Malignant
Advanced Malignant Mesothelioma, Carcinoma of the Appendix
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RATIONALE: An orientation and patient education program and telephone counseling may help improve the quality of life in patients with peritoneal surface malignancies.
- Conditions
- Advanced Malignant Mesothelioma, Carcinoma of the Appendix, Ovarian Sarcoma, Ovarian Stromal Cancer
- Trial name
- HOPE (NCT01126346)
- Testing
- HIPEC Orientation, Consultation with Survivorship Navigator, Questionnaires
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Cancer, Oesophageal Cancer
Nutrition in Gastrointestinal Tumors
Malnutrition and loss of muscle mass frequently occur in patients undergoing chemotherapy and can negatively effect therapy outcome.
- Conditions
- Pancreatic Cancer, Oesophageal Cancer, Colon Cancer, Liver Cancer
- Trial name
- NutriGIT (NCT04476082)
- Testing
- No intervention - observational study only
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- University Medicine Greifswald
GIST, GIST, Malignant
French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients
GIST are rare mesenchymal tumors of the gastrointestinal tract characterized by somatic mutations in the gene encoding the KIT (85%) or the PDGFRα (8%) protein.
- Conditions
- GIST, GIST, Malignant, PDGFR-Alpha D842V
- Trial name
- AVIATOR2020 (NCT04927260)
- Testing
- Patient treated by Avapritinib in real life
- Where
- 7 sites in France
- Volunteers
- 25 people
- Sponsor
- Centre Leon Berard
Gastrointestinal Stromal Tumors
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
This is a extension study of CSTI571B1201 study
- Trial name
- NCT00237172
- Testing
- Imatinib Mesylate
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Cancer, Gastric Neoplasm
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Objective: To follow people with GISTs and collect tumor tissue so that it can be studied in the lab. Eligibility: People age 6 and older who have a GIST.
- Conditions
- Gastric Cancer, Gastric Neoplasm, Gastrointestinal Stromal Sarcoma, Gastrointestinal Stromal Neoplasm
- Trial name
- NCT04557969
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Cancer Institute (NCI)
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating…
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01154452
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumors, Unresectable Solid Tumor
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
This is a prospective, multicenter, observational real-world study to explore the therapy patterns and clinical outcomes of Avapritinib in patients with metastatic or unresectable gastrointestinal stromal tumors.
- Conditions
- Gastrointestinal Stromal Tumors, Unresectable Solid Tumor, Recurrent Metastatic Malignant Neoplasm
- Trial name
- NCT05464875
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Xinhua Zhang, MD
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Gastrointestinal Stromal Tumor
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving imatinib mesylate before surgery may shrink the tumor so that it can be removed.
- Trial name
- NCT00112632
- Testing
- imatinib mesylate, conventional surgery, neoadjuvant therapy
- Where
- 9 sites in Austria, Germany
- Volunteers
- 40 people
- Sponsor
- Technical University of Munich
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Gastrointestinal Stromal Tumors
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
The rationale is to assess the clinical and biological activity of Imatinib and to compare the data with historic data. Additionally this study has been designed to gain more experience with the treatment of GIST in several…
- Trial name
- NCT00293124
- Testing
- Glivec
- Where
- 16 sites in Austria, Bosnia and Herzegovina and 8 more
- Volunteers
- 125 people
- Sponsor
- Central European Cooperative Oncology Group
Gastrointestinal Stromal Tumor
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Phase II trial to study the effectiveness of neoadjuvant and adjuvant imatinib mesylate in treating patients who are undergoing surgery for primary or recurrent malignant gastrointestinal stromal tumor.
- Trial name
- NCT00028002
- Testing
- Conventional Surgery, Imatinib Mesylate
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumors
A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)
Phase I;To investigate the clinically recommended dose of Sunitinib malate (SU011248) following multiple oral dosing in the first cycle (4 consecutive weeks and 2 weeks rest) by reviewing the safety and tolerability.
- Trial name
- NCT00457743
- Testing
- Sunitinib malate (SU011248)
- Where
- 4 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Pfizer
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
GIST, Malignant, CBT
GIST and Memory and Attention Adaptation Training
Cognitive-behavioral therapy (CBT) has been found to be efficacious in the treatment of cancer-related cognitive impairment (CRCI).
- Trial name
- GIST-MAAT (NCT04879979)
- Testing
- MAAT
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pittsburgh
Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors
Trial of Dasatinib in Advanced Sarcomas
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
- Conditions
- Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma, Sarcoma, Ewing's
- Trial name
- NCT00464620
- Testing
- Dasatinib
- Where
- 20 sites in United States
- Volunteers
- 366 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration